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sensitivity of the cytokine to proteases. These results demonstrate that the IFN-α/β and IFN-λ anti-HBV
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rather than systemic, role in antiviral immunity., Yale University School of
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Hepatitis B virus (HBV) is a hepatotropic virus that causes either
acute or chronic hepatitis in infected individuals. Currently, more than
300 million people worldwide are chronically infected with HBV and
are at risk for developing hepatocellular carcinoma (Liang, 2009). It is
well established that interferon (IFN)-γ production is important for
the non-cytopathic control of HBV replication (Guidotti and Chisari,
2006). IFN-γ is secreted by cytotoxic T-lymphocytes and inhibits both
HBV gene expression and replication (Guidotti et al., 1994, 1996). In
contrast to IFN-γ, HBV does not induce IFN-α/β expression (Wieland
and Chisari, 2005), thus enabling HBV to establish infection before the
adaptive immune response can be launched. Although HBV does not
activate IFN-α/β, the virus is sensitive to its antiviral effects. IFN-α
has been used clinically to treat chronic HBV infection, but this
treatment is only effective in a moderate proportion of patients
(approximately 40%) and is associated with signiﬁcant side effects
(Perrillo, 2009), thus limiting its utility.
IFN-λ1, 2, and 3 are members of the class II α-helical cytokine
family (Kotenko et al., 2003; Sheppard et al., 2003), which also
includes IFN-α/β, IFN-γ, and the IL-10 family cytokines. Also known
as the type III IFNs, these cytokines have functional properties similarto those of IFN-α/β, including the activation of Jak/STAT signaling and
induction of IFN-stimulated response element-dependent genes.
Furthermore, the IFN-λ response inhibits the replication of viruses
such as vesicular stomatitis virus (VSV), encephalomyocarditis virus,
and herpes simplex virus type 2 (HSV-2) (Ank et al., 2006; Kotenko
et al., 2003; Sheppard et al., 2003). IFN-λ also blocks HBV and hepatitis
C virus (HCV) replication in cell culture (Robek et al., 2005), but the
molecular mechanism of this inhibition is unknown.
Despite their functional similarities to IFN-α/β, the type III IFNs
structurally resemble the IL-10 family members, in particular IL-22
(Gad et al., 2009). The IFN-λ receptor consists of two subunits, one
that is unique to the IFN-λs (IL-28R1), and the second is the IL-10
receptor subunit IL-10R2 (Kotenko et al., 2003; Sheppard et al., 2003),
which is also a component of the IL-22 receptor (Kotenko et al., 2001;
Xie et al., 2000). While IFN-λ performs antiviral functions, IL-22
increases microbial defense and protects certain types of tissues
(including epithelia and liver) from damage (Radaeva et al., 2004;
Wolk et al., 2004, 2006; Zenewicz et al., 2007). Although the IL-22
receptor is expressed on hepatocytes, recent evidence indicates that
IL-22 lacks direct antiviral activity against HCV (Dambacher et al.,
2008). However, IL-22 may offer protection to infected hepatocytes
through other mechanisms, as mice lacking IL-22 are highly
susceptible to hepatic damage due to inﬂammation (Zenewicz et al.,
2007). It is also currently unknown if IL-22 inﬂuences the signaling or
activity of IFN-λ, or if any crosstalk between receptors occurs.
Though the signaling and in vitro antiviral activity of IFN-λ has
been studied in detail, much less is known about in vivo activity. The
distribution of the IFN-λR complex differs between organs and tissue
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Sommereyns et al., 2008). Current evidence indicates that in mice,
IFN-λmay systemically inhibit some viruses, but primarily acts locally
to prevent infection (Ank et al., 2006; Bartlett et al., 2005; Mordstein
et al., 2008). The IFN-λ response was found to be highest in epithelial
cells and lower in cells of endothelial origin (Sommereyns et al.,
2008). The tissue speciﬁcity of this response suggests that IFN-λmay
have evolved to defend against viral infections in epithelial tissues
(Sommereyns et al., 2008). It is unclear whether IFN-λ is active in the
liver, as IFN-λ is expressed in the mouse liver following infection
(Sommereyns et al., 2008), but was not found to protect mice from
hepatotropic viruses when injected intraperitoneally (Mordstein
et al., 2008).
We previously reported that HBV replication is blocked by IFN-λ
(Robek et al., 2005), but a number of important questions remained
regarding this ﬁnding: What is the molecular mechanism of this
inhibition, and is this mechanism the same as that activated by IFN-α
and IFN-γ? How does the antiviral activity of IFN-λ compare to other
related cytokines such as IL-22? What regulatory mechanisms
contribute to the in vivo activity of this cytokine? In this study, we
found that IFN-λ inhibits HBV replication by limiting the formation of
HBV RNA-containing capsids, identical to the molecular mechanism
induced by IFN-α. Compared to IFN-λ, IL-22 displayed limited
antiviral activity and induced a more restricted hepatocellular gene
expression proﬁle. We also found that IFN-λ2 only weakly inhibited
virus replication in the liver of HBV transgenic mice after intravenous
injection, and that human IFN-λ2 activity in serum correlatedwith the
sensitivity of the cytokine to proteases. These studies further elucidate
the molecular mechanisms of IFN-λ antiviral activity to a medically
important virus.
Results
IFN-λ inhibits HBV replication by preventing assembly of HBV RNA-
containing capsids
During the HBV replication cycle, viral RNA transcribed from
nuclear covalently closed circular viral DNA is encapsidated by the
viral core protein in the cytoplasm. After encapsidation, this
pregenomic RNA is reverse-transcribed by the viral polymerase
protein ﬁrst to single-stranded and then to partially double-stranded
relaxed circular DNA forms prior to virion release from the cell
(Ganem and Prince, 2004). It has previously been shown that IFN-α/β
and IFN-γ inhibit HBV replication by preventing the assembly of HBV
RNA-containing capsids (Wieland et al., 2005). It was therefore
possible that IFN-λ either inhibits a similar step in replication, or a
different point in the HBV life cycle. To determine the step in the HBV
replication cycle where IFN-λ acts, we used an immortalized murine
hepatocyte cell line (TREHBV-V) that expresses HBV under a
tetracycline-inducible promoter (Wieland et al., 2005). The HBV
genome in these cells contains a mutation in the polymerase catalytic
domain (YMDD), preventing the reverse transcription of viral RNA
into DNA. Therefore, immature RNA-containing capsids accumulate
within the cytoplasm without being converted into DNA and released
from the cell.
We ﬁrst determined if IFN-λ treatment reduced the levels of
encapsidated HBV RNA in the cell. For these studies, we used both
human and murine IFN-λ, as we had previously determined that the
murine cells are capable of responding to the human cytokine (data
not shown). Cells were treated with 600 pg/ml of IFN-α(A/D),
100 pg/ml of human IFN-λ1, or 100 pg/ml murine IFN-λ2 for six
hours prior to induction with doxycycline (Fig. 1A). These concentra-
tions were utilized because they represent the minimal amount of
each cytokine necessary to reproducibly inhibit HBV replication in
immortalized mouse hepatocytes (data not shown). Four days post-
induction, total and encapsidated RNA were harvested and analyzedby Northern blot. Similar to IFN-α, neither human IFN-λ1 nor murine
IFN-λ2 signiﬁcantly reduced the total amount of HBV mRNA in the
cells (Fig. 1B). However, treatment with either IFN-λ subtype resulted
in a similar complete loss of encapsidated RNA (Fig. 1B), as had
previously been found with IFN-α/β and IFN-γ (Wieland et al., 2005).
The lossof encapsidatedRNA inducedby IFN-λ couldbedue toeither
an increase in the degradation rate of preformed capsids, or the
prevention of HBV RNA-containing capsid formation. To determine if
IFN-λ promotes capsid degradation, cells were induced to express HBV
RNA for four days, then incubated for 84 h in the absence of doxycycline
to turn off new RNA synthesis and allow the previously expressed RNA
to become encapsidated (Fig. 1A). The cells were then treated for 6, 12,
24, or 36 hwith100 pg/mlofhuman IFN-λ1, andencapsidatedRNAwas
compared to untreated controls over the 36-hour time course.
Encapsidated RNA in IFN-λ-treated cells disappeared at the same rate
as in untreated control cells (Figs. 1C and D), indicating that IFN-λ does
not promote the degradation of HBV RNA-containing capsids. From
these data we conclude that like IFN-α/β and IFN-γ, the cellular
antiviral response elicited by IFN-λ inhibits HBV replication by
preventing the assembly of HBV capsids in the cytoplasm.
Neither IFN-λ nor IFN-α inhibits HBV in HepG2-derived cells
We next examined the anti-HBV activity of IFN-α and IFN-λ using
a human hepatoma derived cell line (HepG2) encoding the HBV
genome [HepG2(2.2.15)] (Sells et al., 1987). Unlike the immortalized
hepatocytes, HepG2 cells have inherent defects in the IFN-mediated
antiviral response (Keskinen et al., 1999). In fact, IFN-α/β only
modestly inhibits HBV replication in HepG2 cells (Biermer et al.,
2003). Both STAT-1 and STAT-2 were phosphorylated to similar
extents 15 min after treatment with either 600 pg/ml IFN-α or
100 ng/ml IFN-λ in HepG2(2.2.15) cells, indicating that the cytokine
receptors are present and responsive in this cell line (Fig. 2A).
However, following a 24-hour treatment with the cytokines, neither
IFN-α nor IFN-λ induced a signiﬁcant reduction in either HBV DNA or
RNA (Fig. 2B). As it is well established that IFN-α inhibits HBV
replication in other systems (McClary et al., 2000; Pasquetto et al.,
2002; Wieland et al., 2000, 2003, 2005), these data suggest that there
is an inherent defect in the IFN response in HepG2 cells that prevents a
full antiviral response against HBV. Therefore, like IFN-α, IFN-λ
inhibits HBV replication in cells that can fully respond to the antiviral
signals induced by the cytokines, but does not in cell lines such as
HepG2 that cannot.
Combinations of IFN-λ with IFN-α/β or IFN-γ induce only modest
increases in antiviral activity against HBV
We previously demonstrated that combinations of IFN-λ and IFN-
α or IFN-γ inhibit HCV and VSV replication to a greater extent than the
individual cytokine treatments alone (Pagliaccetti et al., 2008). The
increased effects were additive when IFN-λwas combined with IFN-α
and synergistic with the combination of IFN-λ and IFN-γ. To
determine if these combined antiviral effects were also observed in
the inhibition of HBV, TREHBV cells were treated in triplicate with
1.2 ng/ml of murine IFN-β, 10 ng/ml of murine IFN-γ, or 100 pg/ml of
murine IFN-λ2 alone or in combination for 12, 24, or 48 h. These
concentrations were chosen based upon the fact that they induce
similar levels of HBV DNA reduction (60–80%) at 24 h post-treatment
when used alone. Cytoplasmic DNA was harvested from the cells and
HBV replication forms were analyzed by Southern blot (Fig. 3).
Although we observed greater HBV inhibition with the combined
treatments than with a single cytokine alone, the increases were no
greater than an additive (i.e. dose-dependent) effect, consistent with
the convergence of the IFN-stimulated antiviral pathways through a
single downstream antiviral mechanism.
Fig. 1. IFN-λ inhibits HBV replication by preventing the assembly of RNA-containing capsids. (A) Schematic of experimental protocols for determining inhibition of capsid
accumulation or degradation. (B) TREHBV-V cells were treated with 600 pg/ml of IFN-α(A/D), 100 pg/ml of human IFN-λ1, or 100 pg/ml of mouse IFN-λ2 for six hours prior to
treatment with 1 µg/ml doxycycline (dox) to induce HBV RNA expression. Four days after induction, total and encapsidated RNA were prepared and analyzed by Northern blot. Blot
shown is representative of three experiments. (C) TREHBV-V cells were induced to express HBV RNA with 1 µg/ml doxycycline for four days. Cells were then cultured in media
without doxycycline for 86 h before treatment with 100 pg/ml of IFN-λ for 6, 12, 24 or 36 h. Total or encapsidated HBV RNA was measured by Northern blot. Blot shown is
representative of three experiments. (D) Quantiﬁcation of encapsidated HBV RNA as determined from phosphorimager analysis. Data points represent the mean of three replicates
and error bars indicate standard error of mean.
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IFN-λ and IL-22 are both members of the class II α helical cytokine
family and share a receptor subunit (IL-10R2) (Donnelly et al., 2004),
and a recent study has demonstrated that these cytokines are also
structurally similar (Gad et al., 2009). These similarities raised the
possibility that IL-22 may also have direct antiviral activity against
HBV, or may inﬂuence the IFN-λ-mediated inhibition of the virus.
HBV-Met cells were treated with 100 ng/ml of murine IL-22 for 1, 3,
or 5 days, and HBV DNA and RNA levels were measured by Southern
blot or RT-qPCR, respectively (Figs. 4A and B). IL-22 treatment
reduced HBV DNA levels (Fig. 4A), but this inhibition was much
weaker (∼2-fold reduction) compared to the strong inhibition by IFN-
λ (N10-fold reduction, as shown in Fig. 3). Although modest, this
inhibition was reproducible and was also found in the Tet-responsive
cell line TREHBV (data not shown), thus ruling out promoter-speciﬁc
effects. In addition, IL-22 had no consistent effect on HBV RNA levels
(Fig. 4B), nor did it inﬂuence the antiviral activity of IFN-λ (Fig. 4C).
Therefore, unlike IFN-λ, the structurally related cytokine IL-22 has
only limited antiviral activity against HBV.
Differences in hepatocellular response to IFN-λ and IL-22
To understand the differences in the IFN-λ and IL-22 responses to
HBV, we examined the gene expression changes induced by these
cytokines in immortalized mouse hepatocytes, and compared these
changes to those induced by IFN-γ and IL-6. We chose these cytokines
for comparison for two reasons. First, like IFN-α/β, IFN-γ potently
inhibits HBV replication in hepatocytes (Guidotti et al., 1994, 1996),
and the IL-22 gene occupies a position in the genome in closeproximity to the IFN-γ gene (Dumoutier et al., 2000), raising the
possibility that the two cytokines could possibly have some similar
characteristics. Second, IL-22 induces a response in keratinocytes that
displays some similarities to the acute phase response elicited by IL-6
(Wolk et al., 2006), but to our knowledge, these responses have not
been directly compared side-by-side in liver cells.
We ﬁrst conﬁrmed that the c-Met immortalized mouse hepato-
cytes (MMHD3) respond to the cytokines. Consistent with reports
that utilized other cell types (Andoh et al., 2005; Wolk et al., 2004,
2006), IFN-γ and IFN-λ2 primarily activated STAT-1 phosphorylation
in the MMHD3 cells, while IL-6 and IL-22 predominately induced
STAT-3 activation (Fig. 5A). We then performed a microarray gene
expression analysis to compare the overall changes in gene expression
induced by IFN-λ and IL-22. Hierarchical clustering of the gene
expression data demonstrated that the IL-22 response is most similar
to IL-6 (Fig. 5B). Many of the gene expression changes induced by IL-
22 are mirrored in the IL-6 response, and several of these genes
(including IFIT2, RSAD2, and USP18) move in the opposite direction
following treatment with IFN-λ or IFN-γ. In order to ensure that the
commonality between IL-22 and IL-6 went beyond their shared
activation levels, we also performed a Gene Set Enrichment Analysis
(GSEA) to identify functional groups that were enriched among the
most differentially expressed genes. Since GSEA operates on a rank-
ordered list of genes without taking into account the magnitude of
differential expression, this method should be less sensitive to the
overall lower levels of gene expression in the IL-22 and IL-6 responses.
Althoughmost of the gene sets that are signiﬁcantly enriched (qb0.1)
in the IL-22 response are also enriched in the other responses, the
extensive overlap between the top-20 gene sets of IL-22 and IL-6,
none of which are shared by IFN-λ or IFN-γ, conﬁrms the similarity
Fig. 4. IL-22 has only limited antiviral activity against HBV compared to IFN-λ.
Differentiated HBV-Met cells that were treated with 100 ng/ml of IL-22 for 1, 3, or
5 days. HBV replication was measured by (A) Southern blot analysis of the HBV relaxed
circle (RC) and single strand (SS) DNA replication forms or (B) Northern blot analysis of
HBV RNA. (C) TREHBV cells were treated with 10 ng/ml of IL-22 or the indicated
amounts of IFN-λ2 alone or in combination. The HBV single strand DNA replication
form was measured by Southern blot 1 or 2 days post-treatment. Ratios were
determined by quantiﬁcation of phosphorimager ﬁles.
Fig. 2. Neither IFN-α nor IFN-λ inhibits HBV replication in HepG2 (2.2.15) cells.
(A) Western blot (WB) analysis of phosphorylated and total STAT-1 and -2 in HepG2
(2.2.15) cells treated with 600 pg/ml of IFN-α(A/D) or 100 ng/ml of IFN-λ for 15 min.
(B) HBV DNA and RNA replication forms in HepG2 (2.2.15) cells treated with 600 pg/ml
of IFN-α(A/D) or 100 ng/ml of IFN-λ for 24 h. HBV relaxed circle (RC) and single-
stranded DNA replication forms were measured by Southern blot (SB) analysis and
compared to the integrated transgene (Tg). The HBV 3.5 and 2.1 kb RNAs were
measured by Northern blot (NB). Southern and Northern blots shown are represen-
tative of two experiments.
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(Fig. 5C).
Inhibition of HBV replication by IFN-λ in mice is weak compared to IFN-
β or IFN-γ
Although IFN-α/β and IFN-λ both inhibit HBV replication in
immortalized hepatocytes with similar efﬁciencies, the activity ofFig. 3. Combinations of IFN-λ with IFN-α/β or IFN-γ induce greater antiviral activity
than individual cytokines alone. TREHBV cells induced with 1 µg/ml Dox were treated
in triplicate with 1.2 ng/ml of IFN-β, 10 ng/ml of IFN-γ, or 100 pg/ml of IFN-λ2 alone or
in combination for 12, 24 or 48 h. Cytoplasmic HBV single-stranded DNAwas measured
by Southern blot (SB) analysis. Relaxed circle DNA forms displayed a similar pattern
(data not shown). Ratios were determined by quantiﬁcation of phosphorimager ﬁles.these cytokines may differ in the liver in vivo. Therefore, we compared
the antiviral activity of murine IFN-λ2 to that of IFN-β and IFN-γ in
HBV transgenic mice. Animals were injected intravenously with the
cytokines, and virus replication in the liver was measured 24 h later
by Southern hybridization of HBV DNA. The inhibition of HBV
replication was only modest in mice that received 100 µg IFN-λ
(b50% reduction), as compared to mice that received 10 µg of either
IFN-β or IFN-γ (N80% reduction) (Fig. 6). Therefore, compared to IFN-
β or IFN-γ, mouse IFN-λ displays lower activity in the liver in vivo after
i.v. injection.
Sensitivity of IFN-λ2 to a serum protease
The relatively low activity of mouse IFN-λ2 in the liver after i.v.
injection led us to question whether the human type III IFNs might be
sensitive to inactivation by serum proteins. We therefore performed
an in vitro assay to measure human IFN-λ1 and IFN-λ2 activity over
time in pooled normal human serum. One microgram of IFN-λ1 or
IFN-λ2, or 50 ng of IFN-α2a was incubated in 100 µl serum for 3, 9, or
24 h at 37 °C, and cytokine activity was then determined by treating
Huh7 cells with aliquots (ﬁnal concentration 10 ng/ml for IFN-λ
or 50 pg/ml IFN-α2a) for 24 h and measuring expression of a
Fig. 5. Differential STAT phosphorylation and transcriptional programs predict anti-HBV activity of IFN-λ and IL-22. (A) Phosphorylated and total STAT-1 and STAT-3 expression in
MMHD3 cells 15 min after stimulation with 100 ng/ml IL-22, IL-6, IFN-λ, or IFN-γ. (B) Heatmap of differentially expressed genes. Colors indicate the log2 average fold change of
genes with an absolute fold change greater than eight in at least one of the treatment groups. The rows and columns are clustered using hierarchical clustering. A similar pattern of
expression is observed when using lower differential expression cutoffs (data not shown). (C) Functional similarity between IL-22 and IL-6. GSEA was used to determine the top-20
enriched functional groups for each of the treatments. Numbers indicate the extent of overlap between up-regulated gene sets across the different treatments (rectangles). The list of
genes displayed in (B) and the functional groups shown in (C) are provided in the Supplementary data.
Fig. 6.Modest anti-HBV activity of IFN-λ in mice. HBV transgenic mice (3–6 animals per
group) were injected intravenously with saline or the indicated amounts of murine IFN-
λ2, IFN-β, or IFN-γ. HBV replication in the liver was measured 24 h post-injection by
Southern blot analysis of HBV relaxed circle and single strand DNA replication forms.
Data represent mean total HBV DNA quantiﬁed by phosphorimager analysis, and error
bars indicate standard error of the mean. P values indicate result of Student's t-test.
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RT-PCR. These ﬁnal concentrations were used because they are the
minimal amounts necessary to induce maximal MxA expression for
each cytokine (approximately 2000-, 1000-, and 500-fold MxA
induction for IFN-α2a, IFN-λ1, and IFN-λ2, respectively; data not
shown). As shown in Fig. 7A, IFN-α2a maintained activity throughout
the time course, dropping only about 15% over 24 h. Similarly, IFN-λ1
displayed only a relatively moderate loss of activity (60% reduction
after 24 h). However, IFN-λ2 showed the greatest loss of activity,
decreasing by 40% after only 3 h and 98% after 24 h.
We hypothesized that the signiﬁcant loss in IFN-λ2 activity may be
due to degradation by proteases in the serum. Therefore, we incubated
IFN-λ2 in the presence or absence of a protease inhibitor cocktail for
24 h as described above. The addition of the inhibitor cocktail to the
serum prevented the loss of IFN-λ2 activity for the full 24 h (Fig. 7B).
We also examined the levels of the IFNproteins in the serumover time.
While the amount of IFN-α and IFN-λ1 stayed relatively constant over
the 24-hour time period, the level of full-length IFN-λ2 rapidly
decreased, and was replaced by a product of smaller molecular weight
(Fig. 7C). Furthermore, the protease inhibitor cocktail blocked this
cleavage/degradation (Fig. 7C). We then tested the inhibitors
comprising the cocktail individually, and while leupeptin, aprotinin,
bestatin, E64, and EDTA had no effect on IFN-λ2 cleavage (data not
shown), the irreversible serine protease inhibitor AEBSF blocked
Fig. 7. Protease inhibitors prevent loss of activity and degradation of IFN-λ in serum. (A) Activity of human IFN-α2a, IFN-λ1, and IFN-λ2 following incubation in human serum at
37 °C for 3, 9, or 24 h. Quantiﬁcation of activity was performed by treating Huh-7 cells with cytokine/serum for 24 h, followed by quantitative RT-PCR analysis of the representative
IFN-stimulated gene MxA. Data are expressed as MxA expression relative to time 0 and are normalized to GAPDH expression. (B) IFN-λ2 was incubated in human serum at 37 °C for
3, 9, or 24 h in the absence or presence of a protease inhibitor cocktail. Quantiﬁcation of activity was performed by treating Huh-7 cells with cytokine/serum for 24 h, followed by
quantitative RT-PCR analysis of the representative IFN-stimulated gene MxA. Data points are the average of three experiments and error bars indicate SEM. (C) Western blots of IFN-
α2a, IFN-λ1, and IFN-λ2 at the indicated time points. (D) AEBSF prevents IFN-λ2 cleavage in serum.
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IFN-λ2 may display lower activity compared to other IFNs due to its
susceptibility to a serum serine protease.
Thrombin efﬁciently cleaves human IFN-λ2
Amino acid sequence alignment and analysis of potential protease
cleavage sites (http://www.expasy.ch/tools/peptidecutter/) identiﬁed
a consensus thrombin cleavage site present in human IFN-λ2 but absent
in IFN-λ1 (Fig. 8A). Consistent with this ﬁnding, we found that
recombinant human thrombin efﬁciently cleaved human IFN-λ2 in a
manner similar to that observed with human serum (Fig. 8B). Similarly,
mouse thrombin cleavedmouse IFN-λ2, although the size of theproduct
differed from that observedwith the human cytokine,whichmay reﬂect
either a different cleavage site or different mobility of the product in
SDS-PAGE. In contrast to IFN-λ2, IFN-λ1was only cleaved at the highest
thrombin concentration (0.1 NIH units) and for the longest incubation
periods (2–4 h) (Fig. 8B). To determine if thrombin was necessary for
IFN-λ2 cleavage in serum, we also tested the effect of the thrombin-
speciﬁc inhibitor hirudin on IFN-λ degradation (Fig. 8C). The addition of
≥5 antithrombin units (ATU) per 50 µl serum completely protected
1 µg IFN-λ2 as well as the more resistant IFN-λ1 from cleavage during
24 h of incubation. Therefore, compared to IFN-λ1, IFN-λ2 displays
greater sensitivity to thrombin proteolytic activity.
Discussion
Molecular mechanism of HBV inhibition
We previously demonstrated that type III interferon inhibits HBV
replication in immortalized mouse hepatocytes (Robek et al., 2005).Although IFN-α and IFN-λ signal through distinct receptors, they
induce nearly identical patterns of gene expression (Doyle et al., 2006;
Marcello et al., 2006; Pagliaccetti et al., 2008; Zhou et al., 2007). Here,
we show that like IFN-α/β and IFN-γ, the antiviral response induced
by IFN-λ inhibits HBV replication by preventing the formation of HBV
RNA-containing capsids in the cytoplasm, demonstrating that the
three innate antiviral pathways are functionally redundant with
respect to HBV inhibition. However, the IFN-induced protein that
actually inhibits HBV replication has not been identiﬁed, and remains
an important area for future investigation.
The effect of IFN-λ on HBV replication in cells derived from the
human hepatoma cell line HepG2 (WT-10; PEB8) has been previously
described (Doyle et al., 2006; Hong et al., 2007). In contrast to our
previous results using immortalizedmouse hepatocytes, these studies
found relatively weak antiviral activity of IFN-λ against HBV
replication in HepG2-derived cells (≤30% reduction with
≥1000 ng/ml IFN-λ1 in Hong et al.; ≈60% reduction with ≥3 ng/
ml PEG-IFN-λ1 in Doyle et al.), a ﬁnding which we also conﬁrm here.
However, unlike the immortalized hepatocytes used in our studies,
HepG2 cells are known to have inherent defects in the IFN-mediated
antiviral response (Keskinen et al., 1999). Despite the fact that they
respond to IFN-α/β as measured by increased STAT-1 phosphoryla-
tion and IFN-stimulated gene expression (Melen et al., 2000), the
replication of viruses such as inﬂuenza and VSV is only weakly
inhibited in these cells (Keskinen et al., 1999). In fact, HBV replication
is known to be much more sensitive to TNF-α than to IFN-α/β in
HepG2 cells (Biermer et al., 2003), even though IFN-α/β inhibitory
activity against HBV is well-characterized in other cell culture and in
vivo models (McClary et al., 2000; Pasquetto et al., 2002; Wieland et
al., 2000, 2003, 2005). Therefore, like IFN-α, IFN-λ inhibits HBV
replication in hepatocyte-derived cells that can fully respond to the
Fig. 8. IFN-λ2 is sensitive to cleavage by thrombin. (A) Amino acid sequence alignment
of IFN-λ1 and IFN-λ2 in the region of a consensus thrombin cleavage site (ΦΦPRXX;
where Φ is a hydrophobic amino acid and X is any non-acidic amino acid). (B) Human
IFN-λ1 and IFN-λ2 or mouse IFN-λ2 were incubated in the presence of the indicated
NIH units of thrombin (human or mouse, respectively) in cleavage buffer (50 mM Tris–
HCl pH 8.0, 2.5 mM CaCl2, 150 mM NaCl) in a total volume of 30 µl. At the time points
indicated, 5 µl aliquots were removed and combined with 5 µl 2× SDS sample buffer for
Western blot analysis. (C) One microgram of human IFN-λ2 or IFN-λ1 was incubated in
50 µl serum in the presence of 1, 5, or 10 ATU of hirudin for 24 h, and cleavage was
determined by Western blot.
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cell lines such as HepG2 that have defects in this pathway.
IL-22 and the innate anti-HBV response
Gad et al. recently determined the crystal structure of IFN-λ and
found a close similarity to the structure of the IL-10 family cytokine IL-
22 (Gad et al., 2009). Because IFN-λ has antiviral activity and IL-22
appears to possess other antimicrobial activities, it was suggested that
these cytokines may both act to defend epithelial cells from different
types of infection (Gad et al., 2009). Though recent evidence indicates
that IL-22 does not protect cells from HCV infection (Dambacher et al.,
2008), it may provide protection through other mechanisms as IL-22
has been identiﬁed as a survival factor for hepatocytes, and IL-22
knockout mice are more susceptible to inﬂammatory hepatic damage
(Radaeva et al., 2004; Zenewicz et al., 2007). To further characterize
the activity of IL-22 in hepatocytes, we tested its antiviral effects
against HBV both alone and in combination with IFN-λ. Although IL-
22 was able to reduce HBV replication, compared to IFN-λ the
response was much weaker (2-fold inhibition compared to 20-fold)
and required both higher concentrations (100 ng IL-22/ml vs. 100 pg
IFN-λ/ml) and a longer treatment time (3–5 days vs. 1–2 days). Thus,
unlike IFN-λ, which strongly inhibits HBV, IL-22 has only minimal
antiviral activity against this virus.
To provide a more complete comparison between the cellular
responses to these cytokines in hepatocytes, we performed a gene
expression analysis to compare the genes induced by IFN-λ and IL-22.
While a number of studies have examined genes induced by IFN-λ in
hepatocyte-derived cell lines (Doyle et al., 2006; Marcello et al.,2006), gene expression data for IL-22 has been limited to keratino-
cytes and colonic subepithelial myoﬁbroblasts (Andoh et al., 2005;
Nograles et al., 2008; Wolk et al., 2006). We found that the proﬁle of
genes induced by IL-22 more closely resembled the proﬁle of IL-6, and
there was no overlap of the most highly induced genes between IL-22
and IFN-λ. Additionally, we found that IL-22 induced a much lower
number of genes overall compared to IFN-λ. Therefore, despite their
structural similarity and the fact that they share a common receptor
subunit, there appears to be minimal functional similarities between
these cytokines with respect to the transcriptional response in mouse
hepatocytes.
Anti-HBV activity of IFN-λ2 in transgenic mice
While the antiviral activity of type III interferon is well established
for many viruses in cell culture, its activity in vivo is less well
understood. Although IFN-λ is produced in the mouse liver in
response to infection, the IFN-λ receptor is expressed at only very
low levels (Sommereyns et al., 2008). Furthermore, while injection of
IFN-λ was shown to reduce hepatic viral titers in mice systemically
infected with HSV-2 (Ank et al., 2006), it did not protect mice against
infection with another hepatotropic virus, Thogotovirus (Mordstein
et al., 2008). We observed only a moderate inhibition (≈50%) of HBV
replication when mice were injected intravenously with murine IFN-
λ2 as compared to that of mice that received murine IFN-β or IFN-γ.
Based on the work of Sommereyns and colleagues, it is likely that low
expression of the IFN-λ receptor in the mouse liver contributes to this
ﬁnding.
The weak activity of IFN-λ2 in mice also led us to examine the
stability of the human type III IFNs in serum. We found that the
decreased activity of human IFN-λ2 in serum correlated with
sensitivity of the cytokine to serum proteases, including thrombin. It
is important to note that we were limited to testing murine IFN-λ2 in
our mouse studies because mice do not encode a functional IFN-λ1
(Lasfar et al., 2006), which also makes direct comparison of the two
cytokines not possible without using human cytokines in mice, which
would have questionable physiological relevance. It should also be
noted that although we used preparations of IFN-λ2 commercially
puriﬁed from E. coli, human IFN-λ2 does not encode a predicted
glycosylation site (Kotenko et al., 2003), so it is unlikely that
glycosylation provides additional stability to the human protein.
However, this may differ in mice, as secreted mIFN-λ2 and IFN-λ3 are
both glycosylated (Bartlett et al., 2005; Lasfar et al., 2006).
Both IFN-α/β and IFN-γ are sensitive to degradation by proteases
(Black, 2002; Cantell et al., 1992; Nelissen et al., 2003), and other
cytokines such as TNF-α, IL-1 and IL-18 also require intracellular
processing by proteases in order to be activated (Fantuzzi and
Dinarello, 1999). Although the degradation of IFN-λ2 by proteases
may be a regulatory mechanism for limiting its activity to a localized
rather than system response, other regulatory mechanisms may also
be important for the control of IFN-λ function in vivo. Interestingly, a
soluble form of the IFN-λ receptor was recently described which
binds to IFN-λ1 and inhibits its activity (Witte et al., 2009), further
supporting the potential importance of precise regulation of this
cytokine family. Additional studies would be necessary to deter-
mine the role of proteases in the systemic and/or local regulation of
IFN-λ produced endogenously during natural infections in mice and
humans.
Understanding the regulation of IFN-λ antiviral activity in vivo is of
particular importance due to the potential for IFN-λ to be used
therapeutically. Phase 1a and 1b clinical trials of pegylated-IFN-λ1
have demonstrated that the cytokine is well tolerated at relevant
doses and capable of reducing HCV viral loads both alone and in
combination with ribavirin. Regulation of IFN-λ activity by means of
protease degradation and other mechanisms, such as differential
receptor expression, may result in a more localized response with
204 N.E. Pagliaccetti et al. / Virology 401 (2010) 197–206fewer side effects, unlike those observed with IFN-α. Further studies
are needed to fully understand the regulation and activity of IFN-λ in
the antiviral response in vivo.
Materials and methods
Cell lines and reagents
Human hepatocellular carcinoma cells (HepG2, Huh7) were
cultured in Dulbecco's Modiﬁed Eagle Medium (DMEM) supplemen-
ted with 100 µg penicillin/ml, 100 U streptomycin/ml, 2 mM L-
glutamine, 1× MEM nonessential amino acids (Invitrogen, Carlsbad,
CA), 1 mM sodium pyruvate, 10 mM HEPES buffer, and 10% heat
inactivated fetal bovine serum (Invitrogen). The HepG2-derived cell
line containing the HBV genome, HepG2(2.2.15), was cultured in the
same manner as the HepG2 cells (Sells et al., 1987). Mouse
immortalized hepatocytes (HBV-Met, TREHBV, TREHBV-V, and
MMHD3) were propagated in RPMI 1640 medium containing
100 ng epidermal growth factor (BD Biosciences)/ml, 16 ng insulin-
like growth factor II/ml, and 10 µg insulin (Sigma, St. Louis MO)/ml.
Human IFN-λ1 and -λ2, murine IFN-λ2, IFN-γ, IL-6, and IL-22 were
purchased from Peprotech (Rocky Hill, NJ). Human IFN-α(A/D) and
IFN-α2a and were purchased from PBL InterferonSource (Piscataway,
NJ). Mouse IFN-βwas provided by Toray Industries (Chiba, Japan) and
purchased from PBL. Normal pooled human serumwas obtained from
Innovative Research (Novi, MI), and protease inhibitors (inhibitor
cocktail P-2714 and hirudin) and recombinant human thrombin were
purchased from Sigma. Mouse α-thrombin was purchased from
American Diagnostica (Stamford, CT).
Transgenic mice
HBV transgenic mice (strain 1.3.32) have been previously
described (Guidotti et al., 1995, 1996), and were provided by
Frank Chisari (The Scripps Research Institute). These animals encode
a 1.3-overlength copy of the HBV genome (serotype ayw), and
reproduce the virus replication cycle from gene expression through
virion release. Groups ofmice in all experimentswerematched for age
(8–12 weeks), gender, and serum HBeAg as determined by ELISA
(International Immunodiagnostics, Foster City, CA) before use. All
procedures were performed in accordance with the Animal Care and
Use guidelines of Yale University.
HBV DNA analysis
Cells were washed in 1× PBS before the addition of 500 µl of total
DNA lysis buffer (50 mM Tris–HCl pH=8.0, 20 mM EDTA, 1% SDS) or
cytoplasmic lysis buffer (150 mM NaCl, 10 mM Tris-base, pH 8.0, 0.5%
Nonidet P-40). Cytoplasmic lysates were transferred to microcen-
trifuge tubes and nuclei were pelleted by centrifugation for 5 min at
12,000 rpm and 4 °C and supernatants were treated with 5 U of
micrococcal nuclease and 1 U of DNase at 37 °C for 30 min, followed
by 20 mM EDTA and 1% SDS to stop nucleases. Both total and
cytoplasmic lysates were digested with 1 mg/ml proteinase K
overnight at 37 °C, and DNA was extracted by phenol/chloroform
extraction. Twenty micrograms of DNA were digested with EcoRV
(TREHBV) or HinDIII (HBV-met and HepG2) overnight at 37 °C prior
to analysis by Southern blotting with a 32P-labeled HBV DNA probe.
Quantiﬁcations were performed by phosphoimager analysis (Fuji
Industries) using ImageGauge software.
HBV RNA analysis
Total RNA was harvested and prepared using the RNeasy Mini Kit
(Qiagen, Valencia, CA). Encapsidated RNA was extracted from cells
by ﬁrst washing with 1× PBS, followed by incubation in 600 µl ofcytoplasmic lysis buffer on ice for 10 min. Lysates were transferred to
microcentrifuge tubes and nuclei were pelleted by centrifugation for
5 min at 12,000 rpm and 4 °C. Three hundred microliters of the
supernatant was used for the extraction of encapsidated RNA as
previously described (Wieland et al., 2005). RNA was dissolved
in 55 µl of water and 25 µl was used for Northern blotting with a
32P-labeled HBV DNA probe.
Quantitative real-time PCR
Reverse transcription and quantitative real-time PCR were
performed as previously described (van den Pol et al., 2007). Brieﬂy,
1 µg of total RNA was reverse-transcribed using the TaqMan reverse
transcription kit (Applied Biosystems, Foster City, CA) with random
hexamers. Quantitative PCR was performed in duplicate using an
Applied Biosystems 7500 real-time PCR system. PCR mixtures
contained 100 ng reverse-transcribed RNA, 12.5 µl SYBR green
reaction mix (Applied Biosystems), and 200 nM sense and antisense
primers in a total volume of 25 µl. The primer sequences used were as
follows: GAPDH, 5′-AAG TAT GAC AAC AGC CTC AAG ATC-3′ (sense),
5′-CTG TGG TCA TGA GTC CTT C-3′ (antisense); MxA. 5′-ACA GGA CCA
TCG GAA TCT TG-3′ (sense), 5′-CCC TTC TTC AGG TGG AAC AC-3′
(antisense); HBV, 5′-CCC GTT TGT CCT CTA ATT CC-3′ (sense), 5′-GTC
CGA AGG TTT GGT ACA GC-3′ (antisense) (Yang et al., 2002). After an
initial incubation at 95 °C for 5 min, PCR ampliﬁcation was performed
by cycling 50 times for 30 s at 95 °C followed by 1 min at 60 °C. Gene
expression was quantiﬁed using the 7500 system Sequence Detection
Software (Applied Biosystems) after normalization to GAPDH expres-
sion. The ΔΔCt method was used for analysis of all quantitative RT-
PCRs.
STAT phosphorylation
Cells were washed once with PBS and lysed with 2× SDS sample
buffer. Extracts were separated on a 10% SDS-polyacrylamide gel,
transferred to a nitrocellulose membrane (Bio-Rad), and probed with
antibodies speciﬁc for phospho-STAT-1 (Y701), STAT-1, phospho-
STAT-2 (Y690) and STAT-2 (Cell Signaling). Proteins were visualized
using LumiGLO chemiluminescent reagents (Cell Signaling) and a Fuji
LAS-3000 cooled CCD camera.
Microarray
Immortalized murine hepatocytes (MMHD3) were differentiated
for 10 days in 2% DMSO prior to treatment with 100 ng/ml of murine
IFN-γ, IFN-λ2, IL-6 or IL-22 for 24 h. Total cellular RNA from two
experiments was collected using the RNeasy Mini Kit (Qiagen), and
RNA concentration and quality were determined by absorbance
spectrophotometry and electrophoresis. Prior to the microarray
analysis, control RT-PCR reactions were performed on the individual
samples to conﬁrm induced expression of GBP1, ISG15 and serum
amyloid A (data not shown). cRNA was prepared according to the
Illumina (Illumina, San Diego, CA) protocol at the Keck Affymetrix
Resource facility at Yale University. Double stranded cDNA was
synthesized from total RNA using the Illumina TotalPrep RNA
Ampliﬁcation Kit with an oligo (dT) T7 primer. Biotin-labeled cRNA
was prepared by in vitro transcription from cDNA then puriﬁed with
the above Ampliﬁcation kit. cRNA (1.5 µg) was then hybridized to the
MouseWG-6 v2 Expression BeadChip, and processing was performed
following standard protocols (Illumina).
Raw microarray data was normalized using the quantile method
in the beadarray package (Dunning et al., 2007). Hierarchical
clusteringwas performedwith Euclidean distance andWard's linkage.
Gene Set Enrichment Analysis (GSEA) was based on GSEA software
provided by the Broad Institute using the classic enrichment statistic
(Subramanian et al., 2005). Genes were ranked according to their
205N.E. Pagliaccetti et al. / Virology 401 (2010) 197–206signal-to-noise ratio between treated and untreated cells. Perturba-
tion and GO gene sets were obtained through the Molecular Sig-
natures Database (MSigDB) (Subramanian et al., 2005).
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